Author Archives for novago_admin

First patient dosed with NG004 in Phase 1b trial for acute spinal cord injury

January 7, 2025 4:47 pm Published by novago_admin Leave your thoughts

NovaGo Therapeutics AG, a clinical-stage biotech company focused on advancing therapeutics for patients with spinal cord injury or diabetic retinopathy,... View Article

Phase 2 study of NG101 for acute spinal cord injury published in The Lancet Neurology

December 19, 2024 4:47 pm Published by novago_admin Leave your thoughts

NovaGo Therapeutics AG announced that its academic collaboration partners — the Nogo-A Inhibition in Spinal Cord Injury Study Group (NISCI)... View Article

Roger Wetli appointed Chief Financial Officer

January 1, 2024 4:47 pm Published by novago_admin Leave your thoughts

NovaGo Therapeutics AG announced that Roger Wetli was appointed Chief Financial Officer of the company, effective January 1, 2024. Roger... View Article

Dr. Stefan Moese appointed Chief Executive Officer

November 1, 2023 2:46 pm Published by novago_admin Leave your thoughts

NovaGo Therapeutics AG announced that Dr. Stefan Moese was appointed Chief Executive Officer, effective November 1, 2023. Dr. Moese leads... View Article